Bayer announced the US FDA has accepted a sNDA and granted Priority Review for the oral androgen receptor inhibitor darolutamide in combination with docetaxel for the treatment of mHSPC.
[Bayer AG]
Home Newsletters US FDA accepts supplemental new drug application (sNDA) and grants priority review...
